Healthcare
Live Price
Offline$96.79
+1.00% today
1Y Change
+55.79%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 250 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rhythm Pharmaceuticals, Inc. (RYTM) is a Healthcare stock with a market cap of $5.84B and listed on NASDAQ. The stock last traded around $96.79 and up 55.8% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +45.8%, EPS growth of +28.3%, a dividend yield of 0.0%. What stands out right now is revenue +45.8%, EPS +28.3%, free cash flow -2.4% with operating margin -101.2% and ROIC -50.1%. Valuation already assumes a fairly strong business story at price/sales 30.8. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RYTM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RYTM
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RYTM Max Drawdown
-35.54%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RYTM and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$3.2M
-86.7% YoY
FY Net Income
-$69.6M
+61.6% YoY
Free Cash Flow
-$151.4M
+14.8% YoY
Revenue Growth
+45.8%
EPS Growth
+28.3%
Gross Margin
89.7%
Net Margin
-103.6%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 190M | 130M | 77M | 24M | 3M |
| Gross Profit | 170M | 117M | 68M | 22M | 3M |
| Operating Income | -192M | -266M | -184M | -179M | -170M |
| EBITDA | -174M | -238M | -168M | -174M | -68M |
| Net Income | -197M | -261M | -185M | -181M | -70M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 54M | 89M | 60M | 128M | 59M |
| Total Assets | 481M | 392M | 333M | 382M | 330M |
| Total Liabilities | 342M | 228M | 163M | 118M | 45M |
| Shareholder Equity | 139M | 165M | 170M | 264M | 284M |
| Total Debt | 246M | 4M | 1M | 2M | 3M |
| Net Debt | 192M | -85M | -59M | -126M | -57M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
146M
+15.8% YoY
Capital Expenditures
5M
-26.9% YoY
Free Cash Flow
151M
+14.8% YoY
Key ratios
Gross Margin
89.7%
Operating Margin
-101.2%
Net Margin
-103.6%
ROE
-179.1%
Debt / Equity
1.77x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.